Evidence map›Paper›PMID 38971757›Full record

ArticleBMC neurology2024

Plasma alpha B crystallin as potential biomarker for predicting pre-operative seizures in glioma.

Yongsheng Xie, Zengxin Qi, Yusheng Tong, Nan Zhou

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC neurology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Yongsheng Xie *Department of Neurosurgery, Huashan Hospital, Shanghai Medical College, National Centre for Neurological Disorders, Shanghai Key Laboratory of Brain Function and Restoration and Neural Regeneration, Shanghai Clinical Medical Centre of Neurosurgery, Neurosurgical Institute of Fudan University, Shanghai, 200040, China.
Zengxin Qi *Department of Neurosurgery, Huashan Hospital, Shanghai Medical College, National Centre for Neurological Disorders, Shanghai Key Laboratory of Brain Function and Restoration and Neural Regeneration, Shanghai Clinical Medical Centre of Neurosurgery, Neurosurgical Institute of Fudan University, Shanghai, 200040, China.
Yusheng TongDepartment of Neurosurgery, Huashan Hospital, Shanghai Medical College, National Centre for Neurological Disorders, Shanghai Key Laboratory of Brain Function and Restoration and Neural Regeneration, Shanghai Clinical Medical Centre of Neurosurgery, Neurosurgical Institute of Fudan University, Shanghai, 200040, China.
Nan ZhouDepartment of Neurosurgery, Huashan Hospital, Shanghai Medical College, National Centre for Neurological Disorders, Shanghai Key Laboratory of Brain Function and Restoration and Neural Regeneration, Shanghai Clinical Medical Centre of Neurosurgery, Neurosurgical Institute of Fudan University, Shanghai, 200040, China. ziegfeld036@163.com.

Funding

National Natural Science Foundation of China 81702175Shanghai Municipal Science and Technology Major Project No.2018SHZDZX01
6 · The paper itself

Abstract

purposeGlioma-associated epilepsy affects a significant proportion of glioma patients, contributing to disease progression and diminished survival rates. However, the lack of a reliable preoperative seizure predictor hampers effective surgical planning. This study investigates the potential of Alpha B crystallin protein (CRYAB) plasma levels as a predictive biomarker for epilepsy seizures in glioma patients.

methodsPlasma samples were obtained from 75 participants, including 21 glioma patients with pre-operative epilepsy, 14 glioma patients without pre-operative epilepsy, and 21 age- and sex-matched control subjects. Additionally, 11 idiopathic epilepsy patients and 8 intractable epilepsy patients served as positive disease control groups. The study utilized ELISA to accurately quantify the circulating levels of CRYAB in the plasma samples of all participants.

resultsThe analysis revealed a significant reduction in plasma CRYAB levels in glioma patients with pre-operative epilepsy and idiopathic epilepsy. The receiver operating characteristic (ROC) curve analysis displayed an impressive performance, indicating an AUC of 0.863 (95% CI, 0.810-0.916) across the entire patient cohort. Furthermore, plasma CRYAB levels exhibited a robust diagnostic capability, with an AUC of 0.9135, a sensitivity of 100.0%, and a specificity of 73.68%, effectively distinguishing glioma patients with preoperative epilepsy from those without epilepsy. The Decision Curve Analysis (DCA) underscored the clinical relevance of plasma CRYAB levels in predicting pre-operative epilepsy in glioma.

conclusionThe findings imply that the reduced levels of CRYAB may assist in prediction of seizure occurrence in glioma patients, although future large-scale prospective studies are warranted.

Indexed as

alpha-Crystallin B ChainBrain NeoplasmsGliomaSeizuresAdultBiomarkersBiomarkers, TumorFemaleHumansMaleMiddle AgedYoung Adultalpha-Crystallin B ChainBiomarkersBiomarkers, TumorCrystallinEpilepsyGliomaPlasma biomarker

Identifiers

PMID38971757
PMCPMC11227141

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.